Schizophrenia, drug companies and the internet

Social Science and Medicine

Volumn 66, Issue 1, 2008, Pages 99-109

  Read, John ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Internet; Marketing; Pharmaceutical companies; Schizophrenia; Websites

Indexed keywords

DISEASE TREATMENT; INTERNET; MARKETING; MEDICINE; MENTAL HEALTH; PHARMACEUTICAL INDUSTRY; VIOLENCE;

ARTICLE; CAUSAL ATTRIBUTION; DISEASE SEVERITY; DRUG INDUSTRY; FUNDING; HEALTH CARE ORGANIZATION; HUMAN; INTERNET; MEDICAL INFORMATION; MEDICAL RESEARCH; SCHIZOPHRENIA; TREATMENT INDICATION; VIOLENCE;

CAPITAL FINANCING; CONSUMER HEALTH INFORMATION; DISCLOSURE; DRUG INDUSTRY; DRUG INFORMATION SERVICES; HUMANS; INFORMATION DISSEMINATION; INTERNET; MARKETING; PATIENT EDUCATION AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; VIOLENCE;

EID: 36348971230     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.socscimed.2007.07.027     Document Type: Article

References (32)

1. Bentall R.P. Madness explained: Psychosis and human nature (2003), Penguin, London
2. Ciompi L. The natural history of schizophrenia in the long term. British Journal of Psychiatry 136 (1980) 413-420
3. Doran E., Kerridge I., McNeill P., and Henry D. Empirical uncertainty and moral contest: A qualitative analysis of the relationship between medical specialists and the pharmaceutical industry in Australia. Social Science & Medicine 62 6 (2006) 1510-1519
4. Fox N.J., Ward K.J., and O'Rourke A.J. The 'expert patient': Empowerment or medical dominance? The case of weight loss, pharmaceutical drugs and the Internet. Social Science & Medicine 60 6 (2005) 1299-1309
5. Griffiths K., and Christensen H. Quality of web based information on treatment of depression: Cross sectional survey. British Medical Journal 321 (2000) 1511-1516
6. Harrison G., Hopper K., Craig T., Laska E., Siegel C., Wanderling J., et al. Recovery from psychotic illness. British Journal of Psychiatry 178 (2001) 506-517
7. Healy D., and Thase M.E. Is academic psychiatry for sale?. British Journal of Psychiatry 182 (2003) 388-391
8. Johannessen, J.O., Martindale, B.V., & Cullberg, J. (Eds.) (2006). Evolving psychosis: Different stages, different treatments. Hove, UK: Routledge.
9. Kingdon D.G., and Turkington D. Cognitive therapy of schizophrenia (2005), Guilford Press, New York
10. Kisely S., Ong G., and Takyar A. A survey of the quality of web based information on the treatment of schizophrenia and Attention Deficit Hyperactivity Disorder. Australian and New Zealand Journal of Psychiatry 37 (2003) 85-91
11. Larkin W., and Morrison A.P. Trauma and psychosis: New directions for theory and therapy (2006), Routledge, Hove, UK
12. Moncrieff J. Is psychiatry for sale? An examinination of the influence of the pharmaceutical industry on academic and practical psychiatry. Maudsley Discussion Paper (2003), Institute of Psychiatry, London
13. Moncrieff J., and Thomas P. The pharmaceutical industry and disease mongering. Psychiatry should not accept so much commercial sponsorship. British Medical Journal 325 (2002) 216
14. Mosher L., Gosden R., and Beder S. Drug companies and schizophrenia: Unbridled capitalism meets madness. In: Read J., Mosher L., and Bentall R. (Eds). Models of madness (2004), Routledge, Hove, UK 116-130
15. Moynihan R., Heath I., and Henry D. Selling sickness: The pharmaceutical industry and disease mongering. British Medical Journal 324 (2002) 886-891
16. Murray, R.M., Jones, P.B., Susser E., van Os, J., & Cannon, M., (Eds.) (2003). The epidemiology of schizophrenia. Cambridge: Cambridge University Press.
17. NAMI. Annual Report (2006), National Alliance on Mental Illness, Arlington, VA
18. Newcombe J.P., and Kerridge I.H. Assessment by human research ethics committees of potential conflicts of interest arising from pharmaceutical sponsorship of clinical research. Internal Medicine Journal 37 (2007) 12-17
19. Pharmaceutical Marketing. (2000). The mark of Zorro. Pharmaceutical Marketing, May 1, 2000. 〈www.pmlive.com〉.
20. Powell J., and Clarke A. Internet information-seeking in mental health. British Journal of Psychiatry 189 (2006) 273-277
21. Read J. Does schizophrenia exist?. In: Read J., Mosher L., and Bentall R. (Eds). Models of madness (2004), Routledge, Hove, UK 43-56
22. Read J. Why promoting biological ideology increases prejudice against people labelled 'schizophrenic'. Australian Psychologist 42 (2007) 118-128
23. Read J., Hammersley P., and Rudegeair T. Why, when and how to ask about child abuse. Advances in Psychiatric Treatment 13 (2007) 101-110
24. Read J., Haslam N., Sayce L., and Davies E. Prejudice and schizophrenia: A review of the 'mental illness is an illness like any other' approach. Acta Psychiatrica Scandinavica 114 (2006) 303-318
25. Read, J., Mosher, L., & Bentall, R.P. (Eds.) (2004). Models of madness: Psychological, social and biological approaches to schizophrenia. Hove, UK: Routledge.
26. Read J., Perry B., Moslowitz A., and Connolly J. The contribution of early traumatic events to schizophrenia in some patients: A traumagenic neurodevelopmental model. Psychiatry: Interpersonal and Biological Processes 64 (2001) 319-345
27. Read J., van Os J., Morrison A.P., and Ross C. Childhood trauma, psychosis and schizophrenia: A literature review with theoretical and clinical implications. Acta Psychiatrica Scandinavica 112 (2005) 330-350
28. Ross C., and Read J. Antipsychotic medication: myths and facts. In: Read J., Mosher L., and Bentall R. (Eds). Models of madness (2004), Routledge, Hove, UK 101-113
29. Schrank B., Seyringer M., Berger P., Katsching H., and Amering M. Schizophrenia and psychosis on the internet. Psychiatrische Praxis 33 (2006) 277-281
30. Silberg W.M., Lundberg G.D., and Musacchio R.A. Accessing, controlling and assuring the quality of medical information on the internet. Journal of American Medical Association 277 (1993) 1244-1245
31. Sharfstein S.S. Big Pharma and American psychiatry: The good, the bad, and the ugly. Psychiatric News 40 16 (2005) 3
32. Shooter M.S. Dancing with the devil? A personal view of psychiatry's relationships with the pharmaceutical industry. Psychiatric Bulletin 29 (2005) 81-83